Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted?
- 706 Downloads
Lifetime supplementation with vitamin K, vitamin D3, and calcium is likely to reduce fractures and increase survival in postmenopausal women. It would be a cost-effective intervention at commonly used thresholds, but high uncertainty around the cost-effectiveness estimates persists. Further research on the effect of vitamin K on fractures is warranted.
Vitamin K might have a role in the primary prevention of fractures, but uncertainties about its effectiveness and cost-effectiveness persist.
We developed a state-transition probabilistic microsimulation model to quantify the cost-effectiveness of various interventions to prevent fractures in 50-year-old postmenopausal women without osteoporosis. We compared no supplementation, vitamin D3 (800 IU/day) with calcium (1,200 mg/day), and vitamin K2 (45 mg/day) with vitamin D3 and calcium (at the same doses). An additional analysis explored replacing vitamin K2 with vitamin K1 (5 mg/day).
Adding vitamin K2 to vitamin D3 with calcium reduced the lifetime probability of at least one fracture by 25%, increased discounted survival by 0.7 quality-adjusted life-years (QALYs) (95% credible interval (CrI) 0.2; 1.3) and discounted costs by $8,956, yielding an incremental cost-effectiveness ratio (ICER) of $12,268/QALY. At a $50,000/QALY threshold, the probability of cost-effectiveness was 95% and the population expected value of perfect information (EVPI) was $28.9 billion. Adding vitamin K1 to vitamin D and calcium reduced the lifetime probability of at least one fracture by 20%, increased discounted survival by 0.4 QALYs (95% CrI −1.9; 1.4) and discounted costs by $4,014, yielding an ICER of $9,557/QALY. At a $50,000/QALY threshold, the probability of cost-effectiveness was 80% while the EVPI was $414.9 billion. The efficacy of vitamin K was the most important parameter in sensitivity analyses.
Lifetime supplementation with vitamin K, vitamin D3, and calcium is likely to reduce fractures and increase survival in postmenopausal women. Given high uncertainty around the cost-effectiveness estimates, further research on the efficacy of vitamin K on fractures is warranted.
KeywordsCost-effectiveness Expected value of perfect information (EVPI) Fracture prevention Postmenopausal Vitamin K
Dr. O. Gajic-Veljanoski is supported by a Canadian Institutes of Health Research (CIHR) Bisby Postdoctoral Fellowship, Dr. A.M. Cheung by a CIHR/Institute of Gender and Health Senior Scientist Award, and Dr. A.M. Bayoumi by a CIHR/Ontario Ministry of Health & Long Term Care Applied Chair in Health Services and Policy Research focusing on Equity in Resource Allocation. This study was performed to fulfill requirements of a PhD degree in Health Policy, Management, and Evaluation (clinical epidemiology field) at the University of Toronto and did not receive any external funding.
Conflicts of interest
- 7.Binkley N, Harke J, Krueger D, Engelke J, Vallarta-Ast N, Gemar D, Checovich M, Chappell R, Suttie J (2009) Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women. J Bone Miner Res 24:983–991PubMedCrossRefGoogle Scholar
- 11.Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, OxfordGoogle Scholar
- 16.National Osteoporosis Foundation (2010) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, WashingtonGoogle Scholar
- 17.The Medical Letter (2008) Drugs for postmenopausal osteoporosis. The Medical Letter 6:67–74Google Scholar
- 22.Statistics Canada (2007) Canada national statistics life tables (2000–2002). Statistics Canada. http://www.statcan.gc.ca/pub/84-537-x/t/txttables/caf.txt. Accessed 27 Jun 2011
- 26.Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, Anderson FH, Cooper C, Francis RM, Donaldson C, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365:1621–1628PubMedCrossRefGoogle Scholar
- 36.Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938PubMedCrossRefGoogle Scholar
- 37.Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875–883PubMedGoogle Scholar
- 44.NSI Vitamin K-1. http://www vitacost com/NSI-Vitamin-K-1?csrc=NTDC-835003001361#IngredientFacts. Accessed 27 Jun 2011
- 45.Glakay. http://www pharmaoffshore com/index php?cPath=426. Accessed 27 Jun 2011
- 46.Glakay (brand). http://buyaldaracream.com/pharma/product_info.php?manufacturers_id=6&products_id=602&osCsid=fd41e6b123f51563354559dd25c5dc18. Accessed 27 Jun 2011
- 47.Consumer Price Index—December 2009. http://www.bls.gov/cpi/. Accessed 27 Jun 2011
- 53.US Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. US Department of Health and Human Services, Office of the Surgeon General, RockvilleGoogle Scholar
- 54.Stevenson M, Lloyd-Jones M, Papaioannou D (2009) Vitamin K to prevent fractures in older women: systematic review and economic evaluation. Health Technol Assess 13:iii–ix, 1–134Google Scholar
- 58.Leslie WD, Berger C, Langsetmo L, Lix LM, Adachi JD, Hanley DA, Ioannidis G, Josse RG, Kovacs CS, Towheed T, Kaiser S, Olszynski WP, Prior JC, Jamal S, Kreiger N, Goltzman D (2011) Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int 22:1873–1883PubMedCrossRefGoogle Scholar